WARRANT AGREEMENTWarrant Agreement • July 31st, 2006 • Viragen Inc • Biological products, (no disgnostic substances) • Florida
WHEREAS, the Company is engaged in a public offering (“Public Offering”) of Units (“Units”) and, in connection therewith, has determined to issue and deliver, on the detachment date described in Section 2.4 below, and from time-to-time thereafter, up to (i) Warrants (“Public Warrants”) to the public investors, and (ii) Warrants to Dawson James Securities, Inc. (“Dawson James”; together with , the “Underwriters”) or its designees (“Underwriters’ Warrants” and, together with the Public Warrants, the “Warrants”) as part of a Unit Purchase Option, dated as of , 2006 (the “Purchase Option”), each Public Warrant evidencing the right of the holder thereof to purchase one share of the Company’s common stock, par value $.01 per share (“Common Stock”), for $ , subject to adjustment as described herein and each Underwriters’ Warrant evidencing the right of the holder thereof to purchase one share of Common Stock for $ , subject to adjustment described herein; and
VIRAGEN, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • July 31st, 2006 • Viragen Inc • Biological products, (no disgnostic substances) • Florida
The undersigned, Viragen, Inc., a Delaware corporation (the “Company”), hereby confirms its agreement with Dawson James Securities, Inc. (“DJS”) and each of the other underwriters named in Schedule I attached hereto (collectively, the “Underwriters” or individually, an “Underwriter”, which term shall also include any underwriter substituted as hereinafter provided in Section 6 hereof), for whom DJS is acting as representative (in such capacity, the “Representative”), as follows:
ContractSupply and Distribution Agreement • July 31st, 2006 • Viragen Inc • Biological products, (no disgnostic substances)
Information marked below by a [ ] has been omitted pursuant to a request for confidential treatment filed separately with the Commission
AMENDMENT 2 DEVELOPMENT, LICENSE AND COLLABORATION AGREEMENT BETWEEN ROSLIN INSTITUTE (EDINBURGH), VIRAGENICS AND VIRAGEN, INC. (the Agreement)Development, License and Collaboration Agreement • July 31st, 2006 • Viragen Inc • Biological products, (no disgnostic substances)
This Amendment 2 to the Agreement is hereby mutually agreed upon by the Parties hereto, as evidenced by authorised signatures below, and is effective from the last date of signature hereof. Unless the context herein otherwise requires, the words and expressions defined in the Agreement and/or in Amendment 1, shall have the same meaning in this Amendment 2.
ContractDevelopment, License and Collaboration Agreement • July 31st, 2006 • Viragen Inc • Biological products, (no disgnostic substances)
Information marked below by a [ ] has been omitted pursuant to a request for confidential treatment filed separately with the Commission.
ContractPatent and Know How Licence • July 31st, 2006 • Viragen Inc • Biological products, (no disgnostic substances) • England
Information marked below by a [ ] has been omitted pursuant to a request for confidential treatment filed separately with the Commission.
ContractSupply and Distribution Agreement • July 31st, 2006 • Viragen Inc • Biological products, (no disgnostic substances)
Information marked below by a [ ] has been omitted pursuant to a request for confidential treatment filed separately with the Commission
COLLABORATIVE RESEARCH AGREEMENT (SK#6624) Effective on the 1st day of February 2002,Collaborative Research Agreement • July 31st, 2006 • Viragen Inc • Biological products, (no disgnostic substances) • New York
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (hereinafter “SKI”), a not-for-profit corporation of the State of New York having offices at 1275 York Avenue, New York, NY 10021, and
LICENSE, DEVELOPMENT AND SUPPLY AGREEMENTLicense, Development and Supply Agreement • July 31st, 2006 • Viragen Inc • Biological products, (no disgnostic substances) • Delaware
This Agreement is made effective on 16th day of November, 2005 by and between Viragen Inc., a company incorporated in Delaware, USA with its principal offices located at 865 SW 78th Avenue, Plantation, Florida, USA, and its Affiliates and Subsidiaries (Viragen) and Kuhnil Pharm. Co., Ltd., a company incorporated in Seoul, Korea with its principal offices located at 237-12 Gong Deok-dong Mapo-gu and its Affiliates and Subsidiaries (Kuhnil);
